NORDIC BIOTECH GENERAL PARTNER ApS: Financial statements 2023
CVR: 26270367
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
NORDIC BIOTECH GENERAL PARTNER ApS (CVR 26270367) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 7,687 and a net result of DKK 35,005 compared with DKK 3,878 the year before. That is a decrease of 34.6% compared with the year before. Equity in the 2023 report amounted to DKK 968,550. The solvency ratio was 97.4%.
- Gross Profit
- DKK 7,687
- Profit/Loss
- DKK 35,005
- Equity
- DKK 968,550
- Total Assets
- DKK 994,613
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 8K | 35K | 969K | - |
| 2022 | - | 12K | 4K | 934K | 0 |
| 2021 | - | 16K | 8K | 930K | 0 |
| 2020 | - | -765K | -784K | 922K | - |
| 2019 | - | 16K | 7K | 1.7M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
NORDIC BIOTECH GENERAL PARTNER ApS has published its annual report for 2022. Gross profit came to DKK 11,750, and the net result was DKK 3,878.
About NORDIC BIOTECH GENERAL PARTNER ApS
NORDIC BIOTECH GENERAL PARTNER ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2001. The company is in liquidation. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Jakob Mosegaard Larsen. The company is owned by TECH GROWTH INVEST ApS and C. HANSEN INVEST ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 163,699 and a net result of DKK 178,169 compared with DKK 67,346 the year before. Equity in the 2025 report amounted to DKK 1,214,065.